(Q37353859)

19 August 2017

1 reference

title

Inhibition of the renin-angiotensin system: is more better? (English)

1 reference

19 August 2017

Sharon Anderson

1

1 reference

PubMed ID

19092813

19 August 2017

Radko Komers

series ordinal

2

1 reference

PubMed ID

19092813

19 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

75

1 reference

19 August 2017

1

1 reference

19 August 2017

12-14

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2008.556

19 August 2017

0 references

cites work

Regression of glomerular injury by losartan in experimental diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

ACE-I and ARBs in early diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Reversal of lesions of diabetic nephropathy after pancreas transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

An extremely high dose of losartan affords superior renoprotection in the remnant model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.556

7 January 2021

Identifiers

DOI

10.1038/KI.2008.556

1 reference

19 August 2017

1 reference

PubMed ID

19092813